Plain-English translation of NCT04099966 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing allogeneic stem cell transplantation (a transplant of blood-forming cells from a matched donor) combined with a special filtering technique that removes certain immune cells before the transplant. The goal is to help people with serious blood cancers like leukemia and lymphoma, as well as inherited blood disorders like sickle cell disease, by replacing their diseased blood system with healthy donor cells while reducing side effects.
Standard stem cell transplants can work well but often cause a serious side effect called graft-versus-host disease (GVHD), where the new donor immune cells attack the patient's body. This trial is testing whether removing specific immune cells before transplant can reduce this harmful reaction while still allowing the transplant to work effectively.
You likely qualify if…
You likely don't qualify if…
You will be admitted to the hospital for several weeks to receive conditioning therapy (chemotherapy and/or radiation) to prepare your body for the transplant, followed by an infusion of the filtered donor stem cells. After transplant, you will stay in the hospital or nearby for close monitoring of engraftment, immune recovery, and any side effects. You will have frequent blood tests, imaging scans, and clinic visits to track how well the transplant is working and monitor your overall quality of life and health.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States